Provectus Pharmaceuticals Inc. To Present At The NYSSA 2006 Biotech & Specialty Pharmaceuticals Industry Conference In New York City
KNOXVILLE, Tenn., Dec. 5 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals announced today that Provectus' CEO Craig Dees, Ph.D., is scheduled to make an investor presentation at the New York Society of Security Analysts' (NYSSA) 10th Annual Biotech & Specialty Pharmaceuticals Industry Conference at 11:40 am Eastern Time on Wednesday, December 13, 2006. The two-day conference is being held at the conference facilities at NYSSA, 1177 Avenue of the Americas, Second Floor, in New York City December 12-13.
A live webcast of the Company's presentation will be available via a link provided at www.pvct.com. An archive of the presentation will begin shortly after the presentation time and will be available for 90 days at www.pvct.com.
About Provectus Pharmaceuticals, Inc.:
Provectus Pharmaceuticals, Inc. is a pioneering pharmaceutical company actively engaged in the design, development, and marketing of pharmaceutical technologies for the treatment of breast cancer, liver cancer, and metastatic melanoma. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company's topical agent Xantryl(TM), a treatment for psoriasis.
The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865-769-4011. For more information, contact the Company at firstname.lastname@example.org or visit the corporate Web site: www.pvct.com.
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.Provectus Pharmaceuticals, Inc.
CONTACT: Investors, Matt Clawson of Allen & Caron Inc, +1-949-474-4300, email@example.com; or Peter Culpepper of Provectus Pharmaceuticals, Inc,+1-865-769-4011, or firstname.lastname@example.org
Web site: http://www.pvct.com//